	US 11,944,708 B2
	Methods of treating central nervous system disorders via administration of nanoparticles of an mTOR inhibitor and an albumin
Neil P. Desai, Pacific Palisades, CA (US); and Shihe Hou, Millington, NJ (US)
Assigned to Abraxis BioScience, LLC, Summit, NJ (US)
Filed by Abraxis BioScience, LLC, Summit, NJ (US)
Filed on Sep. 17, 2020, as Appl. No. 17/024,482.
Application 17/024,482 is a continuation of application No. PCT/US2019/023037, filed on Mar. 19, 2019.
Claims priority of provisional application 62/815,346, filed on Mar. 7, 2019.
Claims priority of provisional application 62/645,634, filed on Mar. 20, 2018.
Prior Publication US 2021/0000752 A1, Jan. 7, 2021
Int. Cl. A61K 9/51 (2006.01); A61K 9/00 (2006.01); A61K 31/436 (2006.01); A61K 39/395 (2006.01); A61P 25/08 (2006.01)

CPC A61K 9/5169 (2013.01) [A61K 9/0019 (2013.01); A61K 31/436 (2013.01); A61K 39/3955 (2013.01); A61P 25/08 (2018.01)]

19 Claims

1. A method of treating a central nervous system (CNS) disorder in an individual, comprising systemically administering to the individual an effective amount of a composition comprising nanoparticles comprising a mammalian target of rapamycin (mTOR) inhibitor and an albumin, wherein the CNS disorder is epilepsy.